Blog
RSS FeedPosted by Michael Wonder on 24 Oct 2024
Driving down the cost of biologics: lessons from a nationalised health care system
18 October 2024 - Few treatments have revolutionised care for people with chronic inflammatory disorders more than biologic and small molecule ...
Posted by Michael Wonder on 03 Jul 2022
NHS saves 1.2 billion pounds on medicines over three years
1 July 2022 - The NHS has saved taxpayers £1.2 billion in just three years, while securing cutting-edge treatments for ...
Posted by Michael Wonder on 24 Jun 2020
Looking back, UK patients unhappy with adalimumab biosimilar switch
24 June 2020 - The UK results show how challenging switching to a biosimilar can be, according to patient groups. ...
Posted by Michael Wonder on 21 Jan 2020
Achieving cost savings with biosimilars will require new strategies, authors say
20 January 2020 - Improving access to fairly priced, quality-assured generics and biosimilars is essential to realizing the potential public ...
Posted by Michael Wonder on 05 Dec 2019
Is it time to look beyond price with biosimilars?
5 December 2019 - While there is no question that falling prices that come with competition are cause for optimism in ...
Posted by Michael Wonder on 10 Oct 2019
Biosimilars in the UK: where are we now and where does the NHS want to go?
9 October 2019 - The UK health service has well over a decade’s experience of dealing with biosimilars, but the ...
Posted by Michael Wonder on 27 Sep 2019
With Brexit looming, what does the future hold for UK biosimilars?
26 September 2019 - If and when the United Kingdom leaves the European Union, the Medicines and Healthcare Products Regulatory Agency ...
Posted by Michael Wonder on 17 Jul 2019
Majority of patients not asked for consent before being switched to a biosimilar, survey finds
17 July 2019 - The preliminary survey results showed that 52% of patients received a letter from hospital about switching to ...
Posted by Michael Wonder on 05 Jun 2019
NHS publishes update on the use of biosimilars
5 June 2019 - The United Kingdom’s National Health Service (NHS) has published a new document for clinical and nonclinical ...
Posted by Michael Wonder on 13 May 2019
HTA frameworks for RA therapies need improvement, researchers say
13 May 2019 - Cost-effectiveness models for the treatment of rheumatoid arthritis first emerged in the early 2000s when highly effective ...
Posted by Michael Wonder on 27 Nov 2018
NHS saves record £300 million by switching to cheaper arthritis drug
26 November 2018 - The NHS is set to save a record £300 million after negotiating deals with five manufacturers ...
Posted by Michael Wonder on 12 Nov 2018
Biosimilar drugs promise to slash health care costs in rich countries
8 November 2018 - The world's top-selling drug now faces biosimilars that are 80% cheaper. ...
Posted by Michael Wonder on 23 Oct 2018
Biosimilar adalimumab: a landmark for NHS medicines optimisation
23 October 2018 - The NHS’s bid to improve patient outcomes and save money by switching costly biological drugs for ...
Posted by Michael Wonder on 27 Sep 2018
With payers under pressure, biosimilars must demonstrate their value
27 September 2018 - In recent years, payers in Europe have been increasing their scrutiny of new therapies as increasingly high-cost ...
Posted by Michael Wonder on 06 Sep 2018
UK lags behind most of Europe in access to biologics for patients with rheumatoid arthritis
4 September 2018 - Global leader in biosimilars, Celltrion Healthcare announces support for the easing of initiation boundaries for biologics that ...